Agenus (AGEN) Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN) today and set a price target of $6.00. The company’s shares closed last Monday at $2.38.

According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -4.7% and a 27.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $6.00.

See today’s analyst top recommended stocks >>

Based on Agenus’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $34.5 million and GAAP net loss of $30.06 million. In comparison, last year the company earned revenue of $6.45 million and had a GAAP net loss of $47.75 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.